Signalling by fibroblast growth factors (FGFs) through FGF receptors (FGFRs) depends on the cell-surface polysaccharide heparan sulphate (HS) [1, 2] . HS has an ordered domain structure of highly diverse saccharide motifs that present unique displays of sulphate, carboxyl and hydroxyl groups [3] . These motifs interact with many proteins, particularly growth factors. HS binds both to FGFs [4-6] and FGFRs [7] , and probably activates signalling by facilitating ligand-induced receptor dimerisation [8, 9] . Nevertheless, the extent to which specific HS saccharide sequences play a regulatory role has not been established. By screening a library of structurally diverse HS decasaccharides in bioassays of FGF signalling mediated by three different FGFR isoforms, we found that saccharides showed specificity for both ligands and receptors; some saccharides selectively activated FGF signalling through different FGFR isoforms, others acted as negative regulators. We conclude that HS saccharides play critical roles in dictating the specificity of ligand-receptor interactions in FGFR signalling. Controlled alterations in HS structures [10] would provide a mechanism for regulation of cellular responsiveness to growth factors that bind HS. 
Recent studies have shown important functional roles for HS that depend on specific structural modifications (see Supplementary material for additional background). Saccharides from the sulphated domains of HS can differentially activate FGF-2 signalling [11, 12] , and cell-type-specific HS chains can regulate ligand-receptor binding [7, 13] . These studies raise the intriguing possibility that distinct HS saccharide sequences regulate FGF-FGFR interactions. To determine the regulatory role of saccharide specificity in FGF signalling, we first prepared a set of size-defined HS saccharides from porcine mucosal HS, a tissue source of HS chains rich in highly complex mixtures of N-and O-sulphated saccharide species [11, 12] . Following treatment with the enzyme heparitinase, the saccharide products were fractionated by size exclusion chromatography to produce size-defined mixtures from dp4 to dp20 (4-20 monosaccharide units) . Using strong anion-exchange high-performance liquid chromatography (SAX-HPLC), we then purified a library of 27 structurally diverse decasaccharide fractions for initial activity screening (Figure 1 ), decasaccharides being the minimal size for FGF-2 activation [12] . Some were single peaks and others were tightly clustered groups of 2-4 peaks that probably represent isomers with slight structural variations (see Supplementary material).
We initially investigated signalling by a single ligand, FGF-2, mediated by the immunoglobulin-like loop IIIc splice variant of the FGFR isoform 1 (FGFR1c) expressed in HS-deficient BaF3 cells, a well-characterised model for systematic comparisons of the responses of FGFR isoforms. In these cells, responses to FGF are dependent on the addition of exogenous activating saccharides or heparin ( [14] ; see also Supplementary material). Activity screening of all the saccharide fractions showed that they had differing abilities to activate signalling by FGFR1c in response to FGF-2 ( Figure 2a ). Whereas some were as active as Preparation of a HS decasaccharide library by high resolution SAX-HPLC. HS decasaccharides were prepared from porcine mucosal HS and subjected to SAX-HPLC as described previously ([16] ; see also Supplementary material). The figure shows a typical preparative run. Multiple separations of 1 mg per run were performed and identical peak fractions (labelled A-Z) pooled, desalted and weighed before bioassay analysis. 
Absorbance (232 nm) heparin, others elicited only intermediate levels of activation or were incapable of supporting FGF-2 signalling. We then determined whether saccharides differed in their ability to activate signalling by FGF-2 mediated by the FGFR isoforms 2 and 3 (FGFR2c and FGFR3c, respectively) expressed in HS-deficient BaF3 cells. Surprisingly, we observed striking differences in the activity profiles of the decasaccharides (Figure 2 ). Some saccharides activated FGFR1c but not FGFR2c (for example, fractions G, H and I) and vice versa (for example, fractions B and D; Figure 2a ,b). In contrast, only a few of the decasaccharide fractions (for example, A and C) activated FGFR3c, and only weakly (Figure 2c ). We subsequently tested the sizedefined HS saccharide mixtures and observed that only very large saccharides (dp ≥ 18) were able to strongly activate FGF-2 signalling mediated by FGFR3c, although weak responses were elicited by fractions in the size range dp12-16 (see Supplementary material). This activity profile is distinct from that for FGF-2 signalling through FGFR1c in which only fractions of size dp12 and larger were able to strongly activate signalling, and the decasaccharide fraction displayed weak activity (~10% of heparin control). This size-dependent difference in FGFR3c activation might reflect an absolute requirement for longer saccharide sequences, or alternatively that smaller specific activating sequences are harboured only within the larger saccharide fractions.
It was also surprising that, for FGFR2c signalling, some of the saccharides (for example, fractions B-E) were considerably more potent than heparin (Figure 2b ), and this behaviour was maintained over a wide range of concentrations (for example, fraction D; see Supplementary material). In contrast, the most potent activators of FGFR1c were similar in maximum activity to heparin (Figure 2a ), although they were typically less potent at lower doses (for example, fraction V; see Supplementary material). To our knowledge, this is the first demonstration of significantly greater activity of HS saccharides than heparin in FGF signalling, and suggests that FGFR2c is not maximally activated by heparin sequences. It should, however, be noted that this comparison is on the basis of weight-equivalent rather than equimolar amounts of saccharides. Their differing lengths and molecular weights (approximately 3 kDa for decasaccharides and 12 kDa for heparin) could contribute to differences in activity and further comparisons with purified heparin decasaccharides will be required to address this point. Heparin is found only in mast cells unlike HS, which is very widely expressed in metazoan organisms and is the predominant physiologically relevant molecule. Our data indicate that use of heparin as a surrogate experimental molecule for HS has precluded recognition of the functional specificity of cellular HS sequences. Moreover, our results also show that previous experiments on the ligand specificity of FGFRs in the presence of heparin [14] do not fully reflect the role that HS saccharides might play in dictating ligand specificity.
As previous studies indicated that some HS saccharides can inhibit FGF-2 activation [12] , we also tested the ability of the decasaccharides to act as negative regulators of FGF-2 signalling. We observed that some saccharides that did not activate FGF-2 signalling through a particular receptor showed no significant activity (for example, fraction R for FGFR1c and FGFR2c), but others (for example, fractions T and X′ for FGFR1c, and V and X′ for FGFR2c) selectively inhibited FGF-2 signalling in the presence of a sub-maximally activating dose of heparin (see Supplementary material). It is notable that these negative regulators were active at concentrations similar to those at which positive regulators were active (30-1000 ng/ml). Moreover, some saccharides that inhibited one FGFR activated a different isoform. In contrast to the unexpected FGFR-specific mode of action of the saccharides, differential effects of specific HS saccharides on signalling by FGFs is expected because of the different structural requirements for binding of HS to various FGFs [4] [5] [6] . To examine this possibility, we tested the ability of the decasaccharide fractions to act as regulators of FGF-1 signalling. In contrast to FGF-2, none of these saccharides activated FGF-1 signalling mediated by FGFR1c in BaF3 cells (data not shown). This indicates a different HS sequence requirement for activation of FGF-1, but an additional factor could be the length of the saccharides. We tested this possibility using the sizedefined HS saccharide mixtures. There was a sharp cut-off in activity, with saccharides dp14 and larger strongly activating FGF-1, the dp12 fraction activating very weakly and smaller fractions being inactive (see Supplementary material). As these size-defined fractions are complex mixtures, it is possible that some individual dp12 saccharides are positive regulators of FGF-1 activity (as observed for the dp10 fraction in the activation of FGF-2). Nevertheless, the activity profile is quite distinct from that for FGF-2 signalling through FGFR1c. As for FGFR3c signalling, the basis for this size-dependent difference remains to be determined.
To demonstrate that the decasaccharide fractions contain molecules with different structures, we analysed the disaccharide compositions of selected fractions with different activities (see Supplementary material). Each had a distinct composition, indicating differences in the primary structure of the constituent saccharides. The profiles of activation did not relate to general changes in charge density and the level of sulphation (elution times correlated broadly with charge density and increased levels of sulphation), indicating that the HS saccharides contain specific structural motifs responsible for their activities. Indeed, variation in the levels of different structural groups, particularly 2-O-sulphates and 6-O-sulphates, was evident from the compositional analysis of the saccharides, consistent with previous evidence that these modifications are critical for regulation of FGF-2 signalling mediated by FGFR1c [6, 12, 15] . Our results extend these observations to the FGFR2c and FGFR3c isoforms, and show for the first time that specific HS saccharide sequences are designed for selective regulatory interactions with the FGFR components of the FGF signalling pathway.
Recently, the primary structure of one of the decasaccharides (the inhibitor designated X′) was established, using a new technique for direct sequencing of HS saccharides ( [16] ; see Supplementary material). Previous work indicated that the position of a 6-O-sulphate group on glucosamine residues is critical for activation of FGF-2 [15] . As 6-O-sulphate groups are not required for FGF-2 binding [4, 5] , this implies that they play a role in interactions with another protein, with the FGFR being a probable candidate [15] . Interestingly, the sequence of X′ indicates positioning of 6-O-sulphates on the two nonreducing end disaccharide units, suggesting that the location of 6-O-sulphates will be either central or reducing terminal in activating saccharides. It has been reported that binding of HS and heparin chains to [17] . We found no evidence to support this view, however, as none of the bioactive decasaccharides we tested (both activators and inhibitors of FGFR1 and FGFR2 signalling) showed any ability to accelerate antithrombin III inhibition of factor Xa (see Supplementary material).
A major goal of future studies will be the further purification and sequencing of sets of individual decasaccharides with similar abilities to regulate FGF-2 signalling mediated by FGFR1c and FGFR2c. It will also be important to determine the activities of individual saccharides from the mixed-peak fractions. The approach we have described can also be extended to larger HS saccharides (for example, those required for activation of signalling by FGF-1 or FGFR3c) and to a wider array of other FGF ligand and receptor isoforms. These studies will permit multiple structural comparisons to be made and allow consensus saccharide motifs for particular activities to be defined. In addition, we will be able to exploit, for the first time, fully defined HS molecules in mechanistic studies on the FGF-FGFR system.
The effects of the HS decasaccharides that we observed are probably exerted through direct interactions with both FGFs and FGFRs, a view supported by recent crystallographic data on an FGF-2-FGFR1 complex [9] and molecular modelling studies [18] indicating that the HS-binding regions of the two proteins are closely positioned in a dimerised ligand-receptor complex. We propose that the mechanism involves the participation of HS saccharide motifs in the ligand-receptor complex in a way that enhances receptor dimerisation, imparts specificity and probably also increases binding affinity. One possible model for these interactions is shown in Figure 3 . The signalling outcome would depend on the balance of different regulatory saccharide motifs expressed on the HS chains; the precise spatial displays of their structural groups would permit distinct interactions with the HS-binding domains of the FGFs and FGFRs. In addition, the receptor specificity we have demonstrated presumably relates to differential interactions between the saccharides and divergent sequences in the HS-binding region of the different FGFR isoforms [9] . Cells can dynamically alter their expression of specific HS sequences, for example, during development [10] . This might provide a new mechanism by which cells fine-tune their spatial and temporal responses to HSbinding extracellular factors, and also restrict signalling by particular ligand-receptor combinations.
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Supplementary background
Recent genetic, biochemical and cell biological studies have highlighted important functional roles for HS in many cellular events including cell division, modulation of signalling molecules, axon navigation, kidney development and neurite outgrowth [S1-S6] . Some of these studies have provided evidence that structural modifications within HS chains are crucial for these functional roles [S3-S5] . The molecular basis for the activities of HS is its ability to interact with and regulate the activities of many proteins, particularly growth factors. The best studied example is the FGF family of growth factors, where signalling through tyrosine kinase FGFRs is known to be dependent on HS. The molecular determinants for the interaction of FGF-2 with HS are now well established, and there is growing evidence that other members of the FGF family recognise different structural motifs in HS [S7,S8] . This suggests the potential for differential binding and regulation of ligands by HS. In addition, there is evidence that FGFRs also interact with both heparin [S9] (a highly sulphated structural analogue of HS) and with HS ([S10]; A. Powell and J.E.T., unpublished observations); although the specificities of the latter interactions are not yet known, they may also be regulatory. The mechanism by which HS saccharides modulate FGF signalling remains to be fully elucidated, but much evidence indicates that it involves facilitation of ligand-induced receptor dimerisation.
Supplementary materials and methods

Saccharide preparation and analysis
Size-fractionated HS saccharides were prepared by heparitinase treatment of porcine mucosal HS (gift from Organon, Oss, Netherlands) and Bio-Gel P-10 size exclusion chromatography as described previously [S11,S12] . These saccharide pools represent complex sulphated sequences enriched in N-sulphated glucosamine, iduronate residues and O-sulphate groups, which are resistant to heparitinase cleavage [S11-S14] . SAX-HPLC of HS saccharides was performed on Propac PA1 columns (4 × 250 mm; Dionex). Samples were eluted with a linear gradient of sodium chloride (0-1.0 M over 90 min) [S15] and 0.2 ml fractions corresponding to selected peaks were pooled, desalted on Sephadex G-25 HiTrap columns (Pharmacia) and weighed before bioassay analysis. SAX-HPLC separation of the decasaccharides produced a highly complex profile of different saccharide peaks (Figure 1) . The tightly clustered groups of peaks were pooled for simplicity for the initial activity screen described here. At least some of the partially resolved peaks represent an equilibrium of α and β anomers of the same primary structure; resolution of these peaks is decreased by running the columns at higher temperatures (data not shown). Others represent different structures (probably sulphation isomers) with slight variations in the disposition of their sulphate groups and glucuronate/iduronate moieties. We are currently applying enhanced separation protocols for these saccharides so that their individual activities can be tested.
Assays for FGF-stimulated mitogenesis
Activation of FGF signalling was measured in bioassays using a lymphoblastoid cell line (BaF3 cells), which lacks both endogenous HS and FGFRs and normally requires addition of IL-3 for survival and growth. Stable transfectants which express specific FGFR isoforms [S16] can be used to screen the abilities of HS saccharides to regulate signalling, as in the absence of IL-3 the cells will grow in response to appropriate FGFs only in the presence of activating HS or heparin Supplementary material Figure 
S1
Differential activation of FGF signalling by size-defined HS saccharides. FGF-2 activation of (a) FGFR1c and (b) FGFR3c. (c) FGF-1 activation of FGFR1c. Activation of FGF-2 signalling was measured in bioassays using HS-deficient BaF3 cells expressing different FGFR isoforms as described in the Supplementary materials and methods. Responses to 1 nM FGF-2 or FGF-1 were assessed in the presence of the size-defined decasaccharide fractions shown (300 nM; equivalent to 1 µg/ml for the dp10 fraction), relative to a positive control of heparin (1 µg/ml). Assays were performed in triplicate and expressed as a percentage (mean ± SD) of the heparin control. Saccharides ≤ dp6 displayed no activity in these assays (data not shown). Saccharide fraction size (dp) Saccharide fraction size (dp)
Current Biology
Saccharide fraction size (dp) Although our assay readout is long term and the events downstream from the receptor not yet well defined, the unequivocal FGFR isoform specificities in otherwise identical cell backgrounds can best be interpreted as involving a common step that is strongly dependent on FGF-FGFR interactions. Previous work has shown that results from BaF3 mitogenic assays and binding of FGFs to soluble FGFRs are in good agreement, indicating that the cell assays accurately reflect effects on these interactions [S18] . The readout from BaF cell assays also agree with data from other cell types made HS dependent by chlorate treatment [S19] .
Measurement of anticoagulant activity of HS decasaccharides
The ability of selected HS decasaccharides (those described in the Table  S1 ) to accelerate antithrombin III inhibition of factor Xa was measured using a commercial assay (Accucolor heparin kit, Sigma, catalogue number CRS 106). Activity in this assay requires the presence of antithrombin-III-binding sites containing a 3-O-sulphate group. None of these decasaccharides displayed any detectable activity at concentrations in the range 0.001-1 µg/ml, despite the parental HS having appreciable activity (approximately 70 U/mg, compared with a porcine intestinal mucosal heparin standard at 174 U/mg).
Structure of decasaccharide X′
The sequence of the inhibitory decasaccharide designated X′ was previously determined by integral glycan sequencing to be ∆HexA-GlcNS(6S)-IdoA(2S)-GlcNS(6S)-IdoA(2S)-GlcNS-IdoA(2 S)-GlcNS-IdoA-GlcNS [S15] . *Regulation of FGF-2 signalling by saccharide fractions: 0, no significant activity; -, inhibitor; +, weak activator (< 25% of heparin control); ++, activator (25-150% of heparin control); +++, strong activator (> 150% of heparin control). † Disaccharide composition was assessed by complete lyase depolymerisation and SAX-HPLC and is expressed as a percentage of total disaccharides (ND, none detected). Briefly, disaccharides were prepared by mixed heparin lyase degradation, tagged with a fluorescent label (2-aminobenzoic acid) and analysed by SAX-HPLC with reference to authentic standards as described previously [S15] . Lyase degradation results in modified disaccharides with ∆4,5-unsaturated uronic acid residues (∆UA), some of which are 2-O-sulphated (2S). The glucosamine residues are either N-acetylglucosamine (GlcNAc) or N-sulphated glucosamine (GlcNS), some of which are 6-O-sulphated (6S). ‡ Fraction T (1 µg/ml) was found to inhibit activation of FGFR1c by FGF-2 in the presence of a sub-maximal activating dose of heparin (100 ng/ml).
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